Treatment Strategies

Translating science into strategy: a rationally designed research program

Each immune phenotype requires specific, essential T-cell activity to reinitiate the antitumour immune response. By characterising these patterns of immune activity, Roche is able to spearhead a program of cancer immunotherapy research that is rationally designed around immune and tumour biology.1,2

Roche is investigating a diverse range of targets based on the characteristics of each immune phenotype1-3*

treatment strategies
  • Immune desert
  • Immune excluded
  • Inflamed
Immune desert

T cells absent from the tumour microenvironment1,2

immune desert targets
  • There is a lack of pre-existing immunity
  • The absence of antitumour T cells in the tumour and the tumour microenvironment is the rate-limiting step
    • Inhibiting PD-L1 alone may not be sufficient to elicit T-cell–mediated immunity

Strategies and investigational targets

Roche is investigating the role of multiple immune mechanisms and targets in combination approaches to restore the antitumour immune response.

Mapping of pathways to phenotypes based on current lead hypotheses. Does not preclude activity in other phenotypes.
*Clinical collaborators.
Immune excluded

T cells cannot infiltrate the tumour microenvironment1,2

immune excluded targets
  • Pre-existing immunity is rendered ineffective due to poor T-cell infiltration into the tumour microenvironment
  • An abundance of antitumour T cells accumulate at the tumour periphery; failure to penetrate through the tumour stroma is the rate-limiting step
    • Inhibiting PD-L1 alone may not be sufficient to elicit T-cell–mediated immunity

Strategies and investigational targets

Roche is investigating the role of multiple immune mechanisms and targets in combination approaches to restore the antitumour immune response.

Mapping of pathways to phenotypes based on current lead hypotheses. Does not preclude activity in other phenotypes.
*Clinical collaborators.
Inflamed

T cells infiltrated, but are not functioning properly1,2

immune inflamed targets
  • Pre-existing immunity in the tumour microenvironment is arrested
  • An abundance of antitumour T cells infiltrate the tumour microenvironment but are not functioning properly
    • Inhibiting PD-L1 can elicit T-cell–mediated immunity, but does not address other immune escape mechanisms

Strategies and investigational targets

Roche is investigating the role of multiple immune mechanisms and targets with combination approaches that restore the antitumour immune response.

Mapping of pathways to phenotypes based on current lead hypotheses. Does not preclude activity in other phenotypes.
*Clinical collaborators.
References 
  1. Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541:321-330. PMID: 28102259
  2. Kim JM, Chen DS. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). Ann Oncol. 2016;27:1492-1504. PMID: 27207108
  3. Bacac M, Fauti T, Sam J, et al. A novel carcinoembryonic antigen T-cell bispecific antibody (CEA TCB) for the treatment of solid tumors. Clin Cancer Res. 2016;22:3286-3297. PMID: 26861458

For offline use follow these steps

By accessing this website from your mobile or tablet, you will be able to download its content for offline use.

  • iOS
  • Android
iOS

1. Access the website from your tablet or mobile using Safari as the browser. Make sure you aren’t in a private navigation window. 
2. Click on () on your browser window
3. Select “Add to Home Screen”

Android

1. Access the website from tablet or mobile using Chrome as the browser. Make sure you aren't in a private navigation window. 
2. Click on the menu icon ( ). 
3. Select "Add to homescreen"